Benzinga
NanoVibronix Inc (NASDAQ: NAOV) reported outcomes from a UroShield study conducted at the University of Southampton in the U.K. Quantitative data from the research indicated a positive effect of UroShield on catheter-associated urinary tract infections (CAUTI) and catheter blockage, with approximately one-third of patients in the study citing a reduction in the frequency of catheter blockages and the need for unscheduled catheter challenges. Furthermore, qualitative data indicated favorable opin
Benzinga